Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CFO David Jin bought 7,605 shares of the company’s stock in a transaction that occurred on Thursday, November 19th. The shares were bought at an average price of $1.87 per share, with a total value of $14,221.35. Following the transaction, the chief financial officer owned 1,700,366 shares of the company’s stock, valued at $3,179,684.42. The trade was a 0.45% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
David Jin also recently made the following trade(s):
- On Wednesday, November 18th, David Jin bought 25,000 shares of Fortress Biotech stock. The shares were bought at an average cost of $1.91 per share, with a total value of $47,750.00.
- On Tuesday, November 17th, David Jin purchased 15,000 shares of Fortress Biotech stock. The stock was bought at an average price of $1.72 per share, for a total transaction of $25,800.00.
Fortress Biotech Stock Performance
Shares of NASDAQ FBIO opened at $1.90 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.83 and a current ratio of 2.93. The company has a market cap of $64.11 million, a P/E ratio of 0.83 and a beta of 1.27. The firm’s fifty day moving average is $2.06 and its two-hundred day moving average is $2.69. Fortress Biotech, Inc. has a 52-week low of $1.64 and a 52-week high of $4.53.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.04. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $21.57 million. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. As a group, analysts anticipate that Fortress Biotech, Inc. will post 2.66 EPS for the current fiscal year.
More Fortress Biotech News
Here’s some of the latest news about FBIO:
- Positive Sentiment: CEO Lindsay Rosenwald and CFO David Jin bought a combined 184,328 shares from November 17–19, investing approximately $340,000. These purchases increased their existing holdings and may signal confidence, although insider buying does not guarantee improving business fundamentals. Insider buying report
- Neutral Sentiment: Zacks Research initiated coverage with a “hold” rating, offering no clear directional signal for the shares. Zacks rating information
- Negative Sentiment: HC Wainwright forecasts EPS of $2.37 for FY2027, below its $2.66 estimate for FY2026. The estimates are not company guidance, but the year-over-year decline could temper optimism. Earnings estimate report
Institutional Trading of Fortress Biotech
Several hedge funds have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Fortress Biotech in the 3rd quarter valued at about $462,000. Squarepoint Ops LLC purchased a new position in Fortress Biotech in the second quarter worth about $47,000. Finally, Renaissance Technologies LLC increased its stake in Fortress Biotech by 22.8% during the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 18,490 shares during the last quarter. 96.51% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on FBIO shares. Weiss Ratings cut Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Wall Street Zen cut Fortress Biotech from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Zacks Research initiated coverage on Fortress Biotech in a research report on Wednesday. They set a “hold” rating for the company. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.00.
Read Our Latest Analysis on FBIO
Fortress Biotech Company Profile
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Featured Articles
- Five stocks we like better than Fortress Biotech
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
